Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by LVW Advisors LLC

LVW Advisors LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,105 shares of the medical research company’s stock after purchasing an additional 269 shares during the period. LVW Advisors LLC’s holdings in Charles River Laboratories International were worth $641,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in CRL. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International during the first quarter worth $41,000. VisionPoint Advisory Group LLC grew its stake in shares of Charles River Laboratories International by 45.1% during the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 65 shares during the last quarter. Brown Brothers Harriman & Co. raised its position in shares of Charles River Laboratories International by 76.0% during the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after acquiring an additional 95 shares during the last quarter. GAMMA Investing LLC acquired a new position in Charles River Laboratories International in the fourth quarter valued at approximately $62,000. Finally, Concord Wealth Partners boosted its holdings in Charles River Laboratories International by 362.5% during the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after buying an additional 203 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CRL. Robert W. Baird downgraded Charles River Laboratories International from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $239.00 to $191.00 in a report on Thursday, August 8th. The Goldman Sachs Group reduced their price target on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Argus restated a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. Finally, TD Cowen decreased their price objective on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating on the stock in a report on Monday. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $231.00.

Charles River Laboratories International Stock Up 0.7 %

Charles River Laboratories International stock traded up $1.44 during mid-day trading on Tuesday, hitting $195.75. The company had a trading volume of 103,439 shares, compared to its average volume of 584,418. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The stock’s 50 day moving average price is $214.72 and its two-hundred day moving average price is $231.28. The company has a market capitalization of $10.08 billion, a PE ratio of 22.86, a price-to-earnings-growth ratio of 2.32 and a beta of 1.38. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International declared that its Board of Directors has approved a share buyback program on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).